Dyadic International, Inc. (NASDAQ:DYAI) is expected to report third quarter earnings results, after market close, on Thursday 12th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.08 per share.
Looking ahead, the full year loss are expected at $ 0.33 per share on the revenues of $ 1.00 million.
Previous Quarter Performance
Dyadic International, Inc. communicated loss for the second quarter of $ 0.10 per share, from the revenue of $ 0.52 million. The quarterly revenues boosted 33.33 percent compared with the same quarter last year. Street analysts expected Dyadic International, Inc. to report loss of $ 0.04 per share on revenue of $ 1.33 million for the second quarter. The bottom line results missed street analysts by $ 0.06 or 150 percent, at the same time, top line results fell short of analysts by $ 0.81 million or 60.9 percent.
Stock Performance
Shares of Dyadic International, Inc. traded low $ -0.23 or -3.33 percent on Wednesday, reaching $ 6.68 with volume of 79.20 thousand shares. Dyadic International, Inc. has traded high as $ 6.89 and has cracked $ 6.61 on the downward trend
The closing price of $ 6.68, representing a 175.30 % increase from the 52 week low of $ 2.51 and a 37.07 % decrease over the 52 week high of $ 10.98.
The company has a market capital of $ 183.58 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Dyadic International, Inc. will be hosting a conference call at 5:00 PM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, (877) 407-8033 or +(201) 689-8033 (International) in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.dyadic.com
Dyadic International, Inc., a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. Dyadic International, Inc.
